←NVECNVEOur view: UnattractiveFull analysisעברית
Updated 16 Nov 2026
The company · 1 · Who is this company?

NVE makes tiny sensors for heart implants

Magnetic sensors

made from films a few atoms thick

Data couplers

send signals without a wire

Minnesota

its own clean room

NVE makes magnetic sensors and data couplers. Heart implants use its sensors to switch into a safe mode.

The company · 2 · What exactly does it sell?

Almost all of it is products

Each $1 of sales, fiscal 2026
96%4%
Product salesPaid research

Paid research for customers is a small extra.

The company · 3 · How does it make money?

Very high profit on tiny sales

79%kept per $1 after making it
60%operating profit per $1
About 37%of sales to Abbott

Costs barely move with sales, so profit swings with each order.

Is it a good business? · 4 · What gives it an edge?

Regulators make a heart-implant part hard to swap

FDA

approval needed to change a safety part

Since 2006

Abbott has been buying

81,606

nerve stimulators corrected for a reed-switch fault

Once inside an approved device, a rival must persuade the maker to pay for testing and a new filing.

Is it a good business? · 5 · What is the catch?

Outside medicine the barrier is lower

Allegrosensors on the same physics
Analog Devicesdata couplers with the same pitch
Littelfuseanother sensor maker

Listed rivals: ALGM · ADI · LFUS

Its larger rivals are many times NVE's size, and its own report says prices are under pressure.

Is it a good business? · 6 · What does its record show?

Tiny, very profitable and flat

Sales, $M
27.0
38.3
29.8
25.9
26.3
31.3
Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026last 12 mo
Sales$38.3M → $31.3Msales, year to March 2023 to the past year
Profit60%operating profit per $1, fiscal 2026
Kept79%kept per $1 after making it

Sales jumped in 2023 and fell back; the profit per dollar barely changed.

Is it a good business? · 7 · How much room is there to grow?

Large markets, an unknown slice

More than 600,000industrial robots installed in 2025
328,027defibrillators implanted in 2009

No one publishes how many magnetic sensors those markets buy, so NVE's slice cannot be checked.

Is it a good business? · 8 · Who is in charge?

A research veteran became chief executive

August 2026Peter Eames became chief executive
48,371shares sold by Daniel Baker outside a plan
2.1%owned by directors and officers

Baker, chief executive since 2001, stays as chairman.

The story right now · 9 · Why do NVE's sales jump around?

Defence orders come and go

55%share jump after June's results
47%sales fall in September
2022, 2023the same pattern before

A small company's sales can jump when one big customer orders. June's jump came partly from defence orders that did not repeat.

The story right now · 10 · Why not trust June's jump?

Twice before, a big quarter faded

  1. A big quarterShares jump.
  2. Orders are rescheduledSales fall back.
  3. Shares fall33.7% in a day.
  4. The price still hopesFor June's level.

In 2022 and 2023 a big quarter lifted the shares and sales fell back. NVE blames timing and expects recovery.

The story right now · 11 · What changed lately?

Sales fell to $5.8M, wiping out June's jump

$5.83Msales, 47% below June
78.2%kept per $1 after making it, held
54.9%operating profit per $1, down
$1.00 vs $0.65dividend against earnings per share, September quarter

Weak quarter

One customer rescheduled orders and defence sales fell.

The story right now · 12 · What is everyone arguing about?

A pause, or a faded spike?

Many investors think

September was a pause after a strong June

We think

Part of June was a defence rebound that faded

Against us: NVE blames timing and expects recovery.

The price and our view · 13 · What is a share worth?

The price sits above even our best case

$56.83what we think a share is worth
$56.83our value
Attractive
below $45.46
Neutral
Unattractive
above $68.20
$40.18gloomy: flat sales, a fifth less kept per $1
$56.83our estimate: experts' path, then slowing
$65.47sunny: flat sales, 68.6% operating profit per $1

Value per share in three futures. None is a prediction of the share price.

We estimate what a share is worth from the cash the business should earn over many years. Our rule: buy only when the price is at least a fifth below our estimate, as a cushion for being wrong.

The price and our view · 14 · How could we be wrong?

The spike has faded

The spike has fadedBiggest

Sales fell back.

Defence swingsShowing now

Fell again.

One big customerWatch

About 37% of sales.

The rescheduled ordersUnknown

Who, how much, when.

Bigger rivals and a dividend above profit add to the risk.

The price and our view · 15 · How will we know?

January tests pause or fade

Sales return to June's levelGood sign
Abbott orders holdGood sign
Defence sales fall againBad sign
JAN 202720

Third-quarter fiscal 2027 results, about 20 January. Companies report every three months; each report is a test of the story.

Our view also changes on price alone: if the shares fall to within a fifth of our estimate, we move to Neutral.

The price and our view · 16 · So, what do we think?

A very profitable sensor maker after a faded spike

$56.83our value
Attractive
below $45.46
Neutral
Unattractive
above $68.20

UnattractiveHigh conviction

NVE keeps about 80 cents of each sales dollar after production costs, and its sensors in heart implants are hard to replace. But sales fell 47% in September, and the price sits above even our sunny future.

↑ ↓ to move · C for contents